In the present study, we demonstrated that regorafenib in combination with rosuvastatin synergistically inhibited colorectal cancer growth by suppressing mitogen-activated protein kinase (MAPK) signaling and promoting the apoptosis of colorectal cancer in vitro and in vivo. Here, WNK2 is linked to colorectal cancer.